Nothing Special   »   [go: up one dir, main page]

HK1030797A1 - In vitro method for dissassembly/reassembly of papillomavirus virus-like particles (vlps) - Google Patents

In vitro method for dissassembly/reassembly of papillomavirus virus-like particles (vlps)

Info

Publication number
HK1030797A1
HK1030797A1 HK01100076A HK01100076A HK1030797A1 HK 1030797 A1 HK1030797 A1 HK 1030797A1 HK 01100076 A HK01100076 A HK 01100076A HK 01100076 A HK01100076 A HK 01100076A HK 1030797 A1 HK1030797 A1 HK 1030797A1
Authority
HK
Hong Kong
Prior art keywords
vlps
particles
dissassembly
reassembly
papillomavirus virus
Prior art date
Application number
HK01100076A
Other languages
English (en)
Inventor
Michael P Mccarthy
Joann Suzich
Original Assignee
Medimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Inc filed Critical Medimmune Inc
Publication of HK1030797A1 publication Critical patent/HK1030797A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK01100076A 1997-09-05 2001-01-04 In vitro method for dissassembly/reassembly of papillomavirus virus-like particles (vlps) HK1030797A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92399797A 1997-09-05 1997-09-05
PCT/US1998/016464 WO1999013056A1 (en) 1997-09-05 1998-08-19 IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs)

Publications (1)

Publication Number Publication Date
HK1030797A1 true HK1030797A1 (en) 2001-05-18

Family

ID=25449564

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100076A HK1030797A1 (en) 1997-09-05 2001-01-04 In vitro method for dissassembly/reassembly of papillomavirus virus-like particles (vlps)

Country Status (16)

Country Link
US (2) US6416945B1 (de)
EP (2) EP1700911B1 (de)
JP (2) JP4199416B2 (de)
AT (1) ATE333501T1 (de)
AU (1) AU742409B2 (de)
CA (1) CA2302545C (de)
CY (2) CY1107987T1 (de)
DE (3) DE69835294T2 (de)
DK (1) DK1015561T3 (de)
ES (2) ES2268787T3 (de)
FR (1) FR07C0012I2 (de)
HK (1) HK1030797A1 (de)
LU (1) LU91314I2 (de)
NL (1) NL300264I2 (de)
PT (1) PT1015561E (de)
WO (1) WO1999013056A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
CA2257822A1 (en) * 1996-07-17 1998-01-22 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Infectious papillomavirus pseudoviral particles
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US7351533B2 (en) * 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
CA2394052C (en) * 1999-12-09 2015-03-17 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
DE60137230D1 (de) * 2000-07-06 2009-02-12 Univ Georgetown Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
DE60143583D1 (de) * 2000-09-18 2011-01-13 Medimmune Llc In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes
CN1114690C (zh) * 2001-05-15 2003-07-16 乔良 乳头瘤假病毒及其制备方法
WO2003068993A1 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10224111A1 (de) * 2002-05-29 2003-12-18 November Ag Molekulare Medizin Verfahren zum Assemblieren von Untereinheiten zu Kapsoiden
ATE521367T1 (de) * 2002-06-07 2011-09-15 Kentucky Bioproc Llc Flexlibler aufbau- und darreichungs-plattform von impfstoffen
DK1572233T3 (da) 2002-12-20 2011-06-27 Glaxosmithkline Biolog Sa Anvendelse af HPV16 og HPV18 som vaccine mod et eller flere onkogene HPV-vira af typerne 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
JP4734608B2 (ja) 2004-07-01 2011-07-27 国立大学法人東京工業大学 生理的条件下でのウイルス粒子様構造体及びその形成方法
US20070041999A1 (en) * 2005-06-01 2007-02-22 Lada Rasochova Production of multivalent virus like particles
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8481693B2 (en) * 2007-03-14 2013-07-09 Takeda Vaccines (Montana), Inc. Virus like particle purification
US20090093019A1 (en) * 2007-04-27 2009-04-09 Phelps Jamie P Production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2008140961A2 (en) 2007-05-08 2008-11-20 The Government Of The U.S.A, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus pseudoviruses for detection and therapy of tumors
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US8663951B2 (en) * 2009-01-09 2014-03-04 Academia Sinica Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
ES2683352T3 (es) 2009-04-13 2018-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale Partículas de HPV y usos de las mismas
PE20120563A1 (es) 2009-06-25 2012-05-17 Glaxosmithkline Biolog Sa Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
WO2011000058A1 (en) * 2009-07-03 2011-01-06 The University Of Queensland A method of preparation of a biological particulate structure
WO2011039646A2 (en) 2009-09-30 2011-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Papilloma virus -like particles for targeted gene delivery
US20130116408A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
US20130115247A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
EP2827891A1 (de) 2012-03-18 2015-01-28 GlaxoSmithKline Biologicals S.A. Impfverfahren gegen humanes papillomavirus
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
EP3517130B1 (de) 2013-09-18 2022-03-30 Aura Biosciences, Inc. Methode zur herstellung photosensitiver moleküle
EA201790365A1 (ru) * 2014-09-11 2017-07-31 Кадила Хелзкэр Лимитед Антигены вируса папилломы человека с хорошими иммунологическими свойствами и содержащая их вакцина
WO2016104923A1 (ko) * 2014-12-26 2016-06-30 아이진 주식회사 인유두종 바이러스의 바이러스 유사 입자 제조방법
JP7115982B2 (ja) 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド 癌の治療のための組成物及び方法
BR112018008390A2 (pt) 2015-10-30 2018-11-27 Aleta Biotherapeutics Inc composições e métodos para transdução tumoral
WO2017075440A1 (en) 2015-10-30 2017-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Targeted cancer therapy
GB201708709D0 (en) * 2017-06-01 2017-07-19 Univ York Virus like particle
AU2018360784A1 (en) 2017-11-06 2020-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cancer treatment utilizing pre-existing microbial immunity
EP3710468A1 (de) 2017-11-14 2020-09-23 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Nicht-menschliche papillomaviren zum gentransfer in vitro und in vivo
GB202011609D0 (en) 2020-07-27 2020-09-09 Univ Leeds Innovations Ltd Coronaviral packaging signals
WO2024111566A1 (ja) * 2022-11-22 2024-05-30 一般財団法人阪大微生物病研究会 安定化されたｖｌｐワクチン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016638A1 (en) * 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Transduction vehicles for transferring dna to a mammalian cell
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique

Also Published As

Publication number Publication date
LU91314I9 (de) 2019-01-30
PT1015561E (pt) 2006-11-30
DE122007000015I1 (de) 2007-05-24
ATE333501T1 (de) 2006-08-15
CA2302545C (en) 2012-04-03
LU91314I2 (fr) 2007-04-23
EP1015561A1 (de) 2000-07-05
FR07C0012I2 (fr) 2007-10-26
JP4199416B2 (ja) 2008-12-17
DE122007000015I2 (de) 2008-01-24
US6261765B1 (en) 2001-07-17
DE69835294T2 (de) 2007-07-26
ES2268787T3 (es) 2007-03-16
EP1700911A1 (de) 2006-09-13
US6416945B1 (en) 2002-07-09
NL300264I2 (nl) 2008-06-02
CA2302545A1 (en) 1999-03-18
CY1107987T1 (el) 2011-04-06
AU742409B2 (en) 2002-01-03
DK1015561T3 (da) 2006-11-13
JP2009057377A (ja) 2009-03-19
CY2007007I1 (el) 2009-11-04
DE69835294D1 (de) 2006-08-31
AU9015498A (en) 1999-03-29
JP4486142B2 (ja) 2010-06-23
WO1999013056A1 (en) 1999-03-18
CY2007007I2 (el) 2016-10-05
EP1700911B1 (de) 2016-04-06
ES2572628T3 (es) 2016-06-01
EP1015561B1 (de) 2006-07-19
FR07C0012I1 (de) 2007-03-30
JP2001515922A (ja) 2001-09-25
NL300264I1 (nl) 2007-05-01

Similar Documents

Publication Publication Date Title
HK1030797A1 (en) In vitro method for dissassembly/reassembly of papillomavirus virus-like particles (vlps)
NZ509610A (en) Process for purifying human papillomavirus virus-like particles using hydroxyapatite
AU5998400A (en) In vitro reconstitution of segmented negative-strand rna viruses
AU8673391A (en) Catalyst composition for purification of exhaust gas, catalyst for purification of exhaust gas, and process for producing said catalyst
AU5873696A (en) Method of preparing 3-haloalkyl-1h-pyrazoles
AU2001266219A1 (en) Novel process for preparing and harvesting crystalline particles
AU2001236042A1 (en) Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
PL317234A1 (en) Vaccines against papilloma virus
EP1394259A3 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
WO2000015251A3 (de) Influenzavirus-impfstoffzusammensetzung
WO2003078455A3 (en) Virus like particle from papillomavirus and their use in vaccine
AU2001266218A1 (en) Process for preparing and harvesting crystalline particles
ATE377076T1 (de) Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
AU2051888A (en) Novel process for purification of hepatitis a virions
AU6704196A (en) Industrial production process for a vaccine against Japanese encephalitis, and vaccine obtained
AU5265296A (en) Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
AU2001237347A1 (en) Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
AU7880494A (en) 5-methyluridine process for large-scale preparation of 2',3'-didehydro-3'-deoxythymidine (d4T)
NZ305188A (en) DNA encoding Human Papilloma Virus (hPV)type 18
CA2333192A1 (en) Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-2h-pyran-2-one
CA2149705A1 (en) Process for producing plant belonging to the section leuce
EP0770626A3 (de) Verfahren zur Reinigung von Thrombomodulin
WO2003022225A3 (en) Compositions comprising mixtures of therapeutic proteins and methods of producing the same
HK1000715A1 (en) Process for producing l-leucine
AU2002213901A1 (en) Method for regenerating a zeolite catalyst

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20180818